Building the future

Strategic partnership with SUDA Pharmaceuticals
November 9th, 2018
This presentation and the accompanying slides (the “Presentation”), which has been prepared by the Company, has been prepared for information purposes only and is not, and is not intended to be, an offer, or solicitation of offer, or invitation or recommendation to buy or sell any securities of the Company, and shall not constitute an offer, solicitation or invitation or recommendation to buy or sell in any jurisdiction in which such offer, solicitation or invitation or recommendation is unlawful. No part, or all, of this Presentation shall form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities of the Company. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration under such act.

Nothing in the foregoing shall constitute and/or deem to constitute an offer or an invitation to an offer, to be made to the Indian public or any section thereof through this document, and this document and its contents should not be construed to be a prospectus in India. This document has not been and will not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India.

This Presentation is strictly confidential and may not be copied, published, distributed or transmitted to any person, in whole or in part, by any medium or in any form for any purpose. The information in this Presentation is being provided by the Company and is subject to change without notice. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This Presentation contains statements about future events and expectations that are forward-looking statements. These statements typically contain words such as “expects” and “anticipates” and words of similar import. Any statement in this Presentation that is not a statement of historical fact is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. None of the future projections, expectations, estimates or prospects in this Presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the Presentation. The Company assumes no obligations to update the forward-looking statements contained herein to reflect actual results, changes in assumptions or changes in factors affecting these statements.

You acknowledge that you will be solely responsible for your own assessment of the market, the market position, the business and financial condition of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company. The distribution of this Presentation in certain jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about and observe any such restrictions.
The company has significantly ramped up its R&D initiatives for the US markets and now reached a run rate of 25 ANDA filings annually. The established portfolio is a diversified basket of products in key dosage formats including soft gels, topicals, modified release products, tablets and includes several Para IV opportunities. Execution of Strides’ generic product pipeline for the US is nearing completion and is expected to have 150+ ANDA filings by 2021. The company is now focusing on developing a portfolio of complex and specialty products including products filed under the 505B (2) regulatory pathway. The specialty portfolio will comprise of new products and reformulations of existing products targeted towards an efficient and effective delivery of drugs, leveraging unique drug delivery technology platforms. The company through inhouse development and partnerships will build a portfolio of limited competition products offering exclusivity for a sustainable period.
Strides Pharma Science Limited (Strides) entered into an exclusive product development, licensing and supply agreement with SUDA Pharmaceuticals Ltd (ASX: SUD) for its novel drug SUD-001H, an oral spray of sumatriptan to treat migraine headache for the US market.

SUD-001H is a first-in-class mint-flavoured oral spray formulation of sumatriptan (marketed in tablet form and in a nasal spray by GlaxoSmithKline under the brand name Imitrex®). Sumatriptan is one of the most widely used drugs for the treatment of acute migraine in adults.

SUDA will provide product development services for SUD-001H funded by Strides. SUDA to work with Strides team through joint committees to achieve successful USFDA approval for the product.

SUDA to receive an upfront cash payment of US$ 0.4 Mn and a further payment of US$ 0.6 Mn on reaching certain milestones including the pilot first-in-man clinical study, submission and approval of the product in the US. On commercial sales, SUDA will receive royalties plus a handling fee.

Strides to have a right of first refusal for additional territories including the European Union, Australia and New Zealand, Canada, South Africa and Japan.

Partnership with SUDA is part of company’s specialty portfolio buildout for the US market.

---

“Global migraine drugs market size was valued at US$ 1.7 Bn in 2017, US migraine drugs market pegged at US$ 1.2 Bn”
Oro-mucosal spray delivery – An efficient drug delivery platform

**Bioavailability across key dosage formats**

<table>
<thead>
<tr>
<th>Dosage Format</th>
<th>Bioavailability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravenous Injection</td>
<td>100%</td>
</tr>
<tr>
<td>Sublingual Spray</td>
<td>95%</td>
</tr>
<tr>
<td>Intra-oral Spray</td>
<td>90% +</td>
</tr>
<tr>
<td>Intra-muscular Injection</td>
<td>90%</td>
</tr>
<tr>
<td>Sublingual in fluid form</td>
<td>50%</td>
</tr>
<tr>
<td>Transdermal Patch</td>
<td>45%</td>
</tr>
<tr>
<td>Gel Capsule</td>
<td>30%</td>
</tr>
<tr>
<td>Capsule - Others</td>
<td>20%</td>
</tr>
<tr>
<td>Tablet</td>
<td>10%</td>
</tr>
</tbody>
</table>

**Bioavailability is in excess of 90% via the oral mucosa**

**DRUG DELIVERY THROUGH ORO MUCOSAL SPRAY**

- Oral mucosa is the lining of the mouth, richly supplied by blood vessels. Oral cavity is ideal for systemic therapy and it avoids metabolism in liver and gut.
- SUDA has developed proprietary oro-mucosal drug delivery technology “OroMist” which enhances absorption of drug via oral mucosa.
- “OroMist” utilizes well-characterized combinations of hydrotropes to shield active drugs from inhibitory intercellular components.
- Ex-vivo and in-vivo studies have shown that hydrotrope technology significantly enhances bioavailability.
- Oro mucosal spray delivery technology enhances drug efficacy with better rate of absorption leading to reduction in dose level and dose variability.
- The technology has a faster onset of action and is more convenient in administration than other dosage format particularly for geriatric and pediatric use.

Source: SUDA PHARMACEUTICALS CORPORATE PRESENTATION
**Migraine**

Migraines are headaches that typically last from 4-72 hours. Patients may experience nausea and vomiting as well as sensitivity to light or sound. Migraine sufferers frequently report throbbing pain that worsens with normal activity. According to the National Headache Foundation, more than 36 Mn Americans suffer from migraine. The drug market value of migraine treatments in the US was estimated to be ~US$1.2 Bn in 2017.

**Strides**

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. The Company has a global manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 facilities for Regulated Markets and 2 facilities for the Emerging Markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com).

**SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa include ease of use, lower dosage, reduced side effects and faster response time. For more information, visit [www.sudapharma.com](http://www.sudapharma.com).
Thank You